法国生物技术公司Abivax S.A.（股票代码：ABVX）今日盘前股价大涨405.70%，引起市场广泛关注。这一惊人涨幅主要源于该公司最新公布的重磅消息。
据悉，Abivax的口服溃疡性结肠炎治疗新药obefazimod在两项大型三期临床研究中取得了突破性进展。试验结果显示，该药物在治疗八周后，在实现临床缓解方面明显优于安慰剂。值得注意的是，近半数参与试验的患者此前对其他先进疗法没有反应，这一结果更加凸显了obefazimod的潜在价值。
Abivax表示，obefazimod的安全性特征与早期试验结果一致，没有出现新的安全问题。公司计划在2026年报告长期维持数据，并有望在当年晚些时候向美国和欧洲监管机构申请药物批准。这一重大突破不仅为溃疡性结肠炎患者带来了新的治疗希望，也大大提升了投资者对Abivax未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.